Breaking News

Takeda to Acquire LigoCyte

Expands vaccine portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda America Holdings, Inc., a subsidiary of Takeda Pharmaceutical Co., will acquire LigoCyte Pharmaceuticals for an upfront payment of $60 million, with future payments based on the progress of development projects. LigoCyte is a privately held biopharma company specializing in vaccine products, and is headquartered in Bozeman, MT. Its lead vaccine product to prevent norovirus gastroenteritis is in Phase I/II development. LigoCyte has also initiated preclinical development of vaccines against...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters